A Companion Diagnostic Study to Develop Circulating Exosomes as Predictive Biomarkers for the Response to Immunotherapy in Renal Cell Carcinoma
Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Observational
SUMMARY
Immune checkpoint inhibitors targeting PD-1 or PD-L1 have been developed and clinical trials showning better response in unselected patients with metastatic renal cell carcinoma (RCC). At the moment, no clear biomarker exists to accurately predict anti-PD1/PDL1 RCC responsiveness. The objective of this study is to develop and evaluate the utility of circulating exosomes as companion diagnostic biomarker for predicting response to immunotherapy in patients with RCC.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Advanced Metastatic RCC
• Scheduled to initiate an immunocheckpoint inhibitors or in combination with them
• Age \>= 18 years
• Able to provide informed consent
Locations
Other Locations
China
An Zhao
RECRUITING
Hangzhou
Time Frame
Start Date: 2023-01-01
Estimated Completion Date: 2025-12-31
Participants
Target number of participants: 100
Related Therapeutic Areas
Sponsors
Leads: Zhejiang Cancer Hospital